Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

CSV in 2026: Computer System Validation for GMP Compliance

Computer system validation in pharma helps companies protect electronic records, control GxP risks, and maintain compliance throughout the validation lifecycle. This guide explains risk-based testing, audit trail review, access control, change control, and inspection-ready evidence.
  • Blog, Validation and Qualification
Pharmaceutical quality specialist reviewing a GxP dashboard for computer system validation in pharma, including audit trail review, access control, testing, and change control.

BMS Builds a Pharma AI Supercomputer: Why Validation Just Got Harder

Bristol Myers Squibb announced on July 20, 2026, that it will expand its artificial intelligence infrastructure through a new NVIDIA DGX SuperPOD equipped with Vera Rubin NVL72 systems. BMS plans to use the infrastructure across several research areas, including oncology,
  • News
BMS Builds a Pharma AI Supercomputer: Why Validation Just Got Harder

PwC Sees $110B Women’s Oncology Market, but Early Detection Still Lags

The global market for women-specific cancers could reach $100 billion to $110 billion by 2030, according to a new PwC report. However, achieving that growth will require more than new investment. Pharmaceutical developers, diagnostic manufacturers and regulators must also close
  • News
PwC Sees $110B Women’s Oncology Market, but Early Detection Still Lags

Pharma Quality Systems in 2026: ICH Q10, GMP Compliance, and PQS Guide

Discover how pharma quality systems based on ICH Q10 strengthen GMP compliance through CAPA, change management, quality risk management, and management review. Learn how an effective pharmaceutical quality system improves inspection readiness, prevents recurring failures, and supports continual improvement.
  • Blog, Quality Management System
Pharmaceutical quality management system infographic showing ICH Q10 elements, CAPA system, quality risk management, and GMP quality controls in pharma manufacturing.

Lilly’s $3.8B Psychedelic Bet, FDA Guidance Shifts Focus to Phase III Risks

Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion as the FDA introduces a clearer regulatory framework for psychedelic drug development. The deal adds the Phase III depression candidate BPL-003 to Lilly’s neuroscience pipeline. More importantly, the
  • News
Lilly’s $3.8B Psychedelic Bet, FDA Guidance Shifts Focus to Phase III Risks

One Phase 3 Win Wasn’t Enough: GSK’s Camlipixant Blockbuster Hope Collapses

GSK has stopped developing camlipixant for refractory chronic cough after mixed results from two Phase 3 trials. Although the drug met one primary endpoint in CALM-1, it failed the primary endpoint in CALM-2 and missed important secondary measures across both
  • News
One Phase 3 Win Wasn’t Enough: GSK’s Camlipixant Blockbuster Hope Collapses

Pharmaceutical QMS Software in 2026: eQMS Features, Compliance, and Validation

Explore how an electronic quality management system strengthens CAPA management, document control, audit trail review, and computerized system validation. This guide explains the core eQMS controls pharmaceutical companies need to maintain GMP compliance and improve inspection readiness.
  • Blog, Computerized System Validation
eQMS software for pharma dashboard supporting CAPA management, computerized system validation, audit trail review, and GMP inspection readiness.

FDA Speeds Reviews in 2026; AI and Old GMP Failures Put Approvals at Risk

Pharmaceutical manufacturing is entering a faster regulatory era. FDA is testing accelerated review models, companies are investing in artificial intelligence, and manufacturers are reconsidering where critical products should be produced. However, FDA’s latest quality data reveal an uncomfortable reality: faster
  • News
FDA Speeds Reviews in 2026; AI and Old GMP Failures Put Approvals at Risk